Ballicules › Drugs › Quetiapine
What it is D2 and 5-HT2A antagonist with strong H1 and alpha-1 blockade; schizophrenia, bipolar disorder and adjunctive depression.
Why this one Its bipolar-depression and adjunctive-depression indications give it unusually broad mood utility for an antipsychotic.
What limits it Sedation, orthostasis and metabolic burden occur even at insomnia doses. Strong CYP3A4 modifiers markedly change exposure.
FDA-approved for
schizophrenia (1997) bipolar mania (2004) bipolar depression (2006) adjunct for depression (2009)
Off-label
FDA label
Read the full label on DailyMed ↗
BOXED WARNING Increased mortality in elderly patients with dementia-related psychosis; increased suicidal thoughts and behaviors in children, adolescents, and young adults.
FDA dosing Population Start Target Max
Schizophrenia Adults 25 mg BID 150-750 mg/day 750 mg/day
Schizophrenia Adolescents 13-17 y 25 mg BID 400-800 mg/day 800 mg/day
Bipolar mania (monotherapy or adjunct to lithium/divalproex) Adults 50 mg BID 400-800 mg/day 800 mg/day
Bipolar mania (monotherapy) Children/Adolescents 10-17 y 25 mg BID 400-600 mg/day 600 mg/day
Bipolar depression Adults 50 mg QHS 300 mg/day 300 mg/day
Titration Schizophrenia adults: after Day 4, further adjustments in 25-50 mg BID increments at intervals of not less than 2 days.
Renal Undefined
Hepatic Lower starting dose (25 mg/day) and slower titration may be needed
Instructions May be taken with or without food Elderly: consider lower starting dose (50 mg/day), slower titration, careful monitoring
Cautions Neuroleptic malignant syndrome Metabolic changes: hyperglycemia/diabetes, dyslipidemia, weight gain Tardive dyskinesia Orthostatic hypotension; falls Cerebrovascular events in elderly with dementia Increased blood pressure in children/adolescents Leukopenia/neutropenia/agranulocytosis QT prolongation Seizures Hypothyroidism, hyperprolactinemia Cataracts Anticholinergic effects; discontinuation syndrome
Adverse reactions Adults: somnolence, dizziness, dry mouth, constipation, asthenia, abdominal pain, postural hypotension, weight gain, ALT increased, dyspepsia Children/adolescents: somnolence, dizziness, fatigue, increased appetite, nausea, vomiting, dry mouth, tachycardia, weight increased
Pregnancy No established drug-associated risk of birth defects; third-trimester exposure risks neonatal extrapyramidal and/or withdrawal symptoms.
Lactation Undefined
⚠ BOXED WARNING
Increased mortality in elderly patients with dementia-related psychosis
Cost, est. cash $4–$80/month
Generic entry 2012
Classes and tags
Clinical profile
Therapeutic safety burden 2 / 4
Overdose danger 2 / 4
Weight-gain liability 3 / 4
Sedation liability 3 / 4
QT / Torsades 1 / 4
Direct muscarinic antagonism 2 / 4
Embryofetal risk 2 / 4
Legacy pregnancy category C
Defining liability Metabolic effects, extrapyramidal symptoms/tardive dyskinesia and agent-specific QT or orthostatic risk.
Active metabolites
Mechanism of action: Quetiapine ballicule
Open Quetiapine in the interactive console ↗
Memory aids: mascots and interaction avatars
“Sera, Quit typing!” Spooky mascot → antipsychotic Crown → antihistamine Polka dots on pink → α1 blocker → syncope if titrated too quickly (hit the floor) QT prolongation For mania (typing all night)
Open Quetiapine in the interactive console ↗